# A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

> **NCT00658671** · PHASE1 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** ENMD-2076

## Key facts

- **NCT ID:** NCT00658671
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-12
- **Final completion:** 2012-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658671, "A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00658671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*